<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287741</url>
  </required_header>
  <id_info>
    <org_study_id>BO21005</org_study_id>
    <secondary_id>2010-024194-39</secondary_id>
    <nct_id>NCT01287741</nct_id>
  </id_info>
  <brief_title>A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)</brief_title>
  <official_title>A Phase III, Multicenter, Open-Label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, randomized, parallel group study will evaluate the efficacy and safety of
      obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone
      or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously
      untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large
      B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000
      milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter
      (mg/m^2) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV
      every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two
      doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2011</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">April 29, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS), Investigator-Assessed</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR), Investigator-Assessed</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR), IRC-Assessed</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) at the End of Treatment, Investigator-Assessed</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) at the End of Treatment, IRC-Assessed</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS), Investigator-Assessed</measure>
    <time_frame>Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non-protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS), Investigator-Assessed</measure>
    <time_frame>Baseline up to death or disease progression, whichever occurred first, to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Disease-free survival was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/relapse or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Reported is the percentage of participants with event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR), Investigator-Assessed</measure>
    <time_frame>Baseline up to death or disease progression, whichever occurs first, to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: &gt;/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression &gt;/= 50%. Progression/relapse: at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 cm or &gt;/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Anti-Lymphoma Treatment (TTNALT)</measure>
    <time_frame>Baseline up to start of next anti-lymphoma treatment or death due to any cause, whichever occurred first, to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab</measure>
    <time_frame>Pre-dose (Hour 0) on Cycle (C) 1 Day (D) 1, C4D1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)</time_frame>
    <description>The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score</measure>
    <time_frame>Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 4 years and 9 months, (cycle length = 21 days)</time_frame>
    <description>The FACT-Lym subscale was developed to assess health-related quality of life in patients with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores</measure>
    <time_frame>Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 4 years and 9 months, (cycle length = 21 days)</time_frame>
    <description>The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)</measure>
    <time_frame>C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)</time_frame>
    <description>Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1418</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab+Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obinutuzumab+Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab at a dose of 375 mg/m^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.</description>
    <arm_group_label>Rituximab+Chemotherapy</arm_group_label>
    <other_name>MabThera, Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.</description>
    <arm_group_label>Obinutuzumab+Chemotherapy</arm_group_label>
    <other_name>GA101, RO5072759</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Rituximab+Chemotherapy</arm_group_label>
    <arm_group_label>Obinutuzumab+Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Rituximab+Chemotherapy</arm_group_label>
    <arm_group_label>Obinutuzumab+Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Rituximab+Chemotherapy</arm_group_label>
    <arm_group_label>Obinutuzumab+Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.</description>
    <arm_group_label>Rituximab+Chemotherapy</arm_group_label>
    <arm_group_label>Obinutuzumab+Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated CD20-positive DLBCL

          -  At least 1 bi-dimensionally measurable lesion (greater than [&gt;]1.5 centimeters [cm] in
             its largest dimension on the computed tomography [CT] scan)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

          -  Adequate hematological function

          -  Low-intermediate, high-intermediate or high-risk International Prognostic Index (IPI)
             score (low-risk IPI score: IPI 1 irrespective of bulky disease or IPI 0 with bulky
             disease, defined as one lesion greater than equal to (&gt;/=) 7.5 cm)

          -  Left ventricular ejection fraction (LVEF) &gt;/=50 percent (%) on cardiac multiple-gated
             acquisition (MUGA) scan or cardiac echocardiogram

        Exclusion Criteria:

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies or known sensitivity or allergy to murine products or to any component of
             CHOP or obinutuzumab

          -  Contraindication to any of the individual components of CHOP, including prior receipt
             of anthracyclines

          -  Participants with transformed lymphoma and participants with follicular lymphoma IIIB

          -  Prior therapy for DLBCL, with the exception of nodal biopsy or local irradiation

          -  Prior treatment with cytotoxic drugs or rituximab for another condition (for example,
             rheumatoid arthritis) or prior use of an anti-CD20 antibody

          -  Prior use of any monoclonal antibody within 3 months of the start of Cycle 1

          -  Corticosteroid use of &gt;30 milligrams per day (mg/day) of prednisone or equivalent, for
             purposes other than lymphoma symptom control

          -  Primary central nervous system (CNS) lymphoma and secondary CNS involvement by
             lymphoma, mantle-cell lymphoma (MCL), or histologic evidence of transformation to a
             Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, plasmablastic
             lymphoma, and primary cutaneous DLBCL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ironwood Cancer TX &amp; Rsch Ctrs</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence, Inc.</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>cCare</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA - School of Medicine; Division of Hematology/Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists; Department of Oncology</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901-8101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists; Saint Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Georgia Cancer Care PC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care, P.C. - Galesburg</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology; Associates, Ltd.</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care &amp; Hematology; Specialists of Chicagoland</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Oncology / Hematology Center; Oncology</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clin-Cancer Ctr</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mecklenburg Medical Group Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical; Research Center, LLC</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland CL N Coast Cancer Cr</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Insitute and Research Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of SC (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates - SCRI</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology and Hematology Associates, PC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Onc., PLLC - SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, Pa - Amarillo</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Fort Worth 12th Ave</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Department of Lymphoma &amp; Myeloma</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas-HOAST - San Antonio</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists - Winchester</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital &amp; Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Damic</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Britanico: Hematologia</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque de Rosario</name>
      <address>
        <city>Rosario</city>
        <zip>S2000DSV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cairns Base Hospital; Cancer Care Centre</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital; Oncology/Haematology</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre; Haematology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie &amp; Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie &amp; Hämostaseologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mae de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas - PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Oncologicas - CEPON</name>
      <address>
        <city>Florianopolis</city>
        <state>SC</state>
        <zip>88034-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa Sao Lucas - IEP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01236-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Marcelina;Oncologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre; Dept of Medicine</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre; Oncology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2J 1V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network; Princess Margaret Hospital; Medical Oncology Dept</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve- Rosemont; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chum Hopital Notre Dame; Centre D'Oncologie</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mcgill University - Royal Victoria Hospital; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de L'Enfant-Jesus; Hematology</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de sante et de services sociaux Rimouski Neigette</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre; Uni of Saskatoon Campus</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences.</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)</name>
      <address>
        <city>Beijing</city>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital of Ministry of Health; Hematology</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Chinese PLA; Department of Hematology</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hu Nan Provincial Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <zip>410006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fujian</city>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yet-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University(First Hospital of Zhejiang</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital to Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <zip>210036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliate Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <zip>215004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiehe Hospital, Tongji Medical College Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center</name>
      <address>
        <city>Wuhan</city>
        <zip>430023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)</name>
      <address>
        <city>Xi'an</city>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardioinfantil</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Sanitas Internacional</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FOSCAL</name>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fn Hr. Kralove; IV. Interni Hematologicka Klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Righospitalet, Haematologisk Klinik</name>
      <address>
        <city>Kobenhavn</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sygehus Syd Roskilde; Onkologisk/haematologisk ambulatorium</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Hæmatologisk Afdeling R</name>
      <address>
        <city>Århus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen; Med. Klinik IV; Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammz</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Kurfürstendamm</name>
      <address>
        <city>Berlin</city>
        <zip>10707</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum &quot;Carl Gustav Carus&quot;; Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Alexander-Universität Erlangen-Nürnberg; Medizinische Klinik V</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Justus-Liebig-Universität; Innere Medizin</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Heidelberg, Medizinische Klinik &amp; Poliklinik V</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Hämatologie / Onkologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital; Department of Medicine</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital; Dept of Medicine</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, First Dept of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology, A Dept of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petz Aladar Megyei Korhaz; Hematologia</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pecs, I st Dept of Internal Medicine</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Szeged, II Dept of Internal Medicine</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Riuniti; Divisione Di Ematologia</name>
      <address>
        <city>Reggio Calabria</city>
        <state>Calabria</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Policlinico, Ii Facolta; Divisione Di Ematologia</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;A.Tortora&quot; - Ematologia; Dipartimento Di Ematologia</name>
      <address>
        <city>Pagani (Sa)</city>
        <state>Campania</state>
        <zip>84016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia; Clinica Ematologica</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Martino Di Genova; Ematologia 1</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ist. Nazionale Per Lo Studio E Cura Dei Tumori; Div. Ematologia Trapianto Midollo Osseo Allogenico</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Policlinico San Matteo; Divisione Di Ematologia</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia</name>
      <address>
        <city>Alessandria</city>
        <state>Piemonte</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti del Canavese</name>
      <address>
        <city>Ivrea</city>
        <state>Piemonte</state>
        <zip>10015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Piemonte Est Amedeo Avogadro; Div.Ematologia- Dip.Clinica Med.Sperim.&amp; Ircad</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. S. Luigi Gonzaga; S.C.D.U. Medicina Interna Ii</name>
      <address>
        <city>Orbassano</city>
        <state>Piemonte</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni Degli Studi Di Bari, Policlinico; Cattedra Di Ematologia,Dipart. Di Medicina Interna E Publica</name>
      <address>
        <city>Bari</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo Della Sofferenza; Ematologia E Trapianto Di Midollo Osseo</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Puglia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. C. Panico; Rep. Ematologia E Trapianto</name>
      <address>
        <city>Tricase - LE</city>
        <state>Puglia</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Univ</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Papardo; Struttura Complessa Di Ematologia</name>
      <address>
        <city>Messina</city>
        <state>Sicilia</state>
        <zip>98165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Univ</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Chiara; Unita Operativa Di Ematologia</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. S. Maria; Dept. Di Oncologia Medica</name>
      <address>
        <city>Terni</city>
        <state>Umbria</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca Foncello; Ematologia</name>
      <address>
        <city>Treviso</city>
        <state>Veneto</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uni Di Verona Policlinico G.B. Rossi; Divisione E Cattedra Di Ematologia</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37130</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Di Vicenza; Nefrologia, Ematologia</name>
      <address>
        <city>Vicenza</city>
        <state>Veneto</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital; Hematology &amp; Oncology</name>
      <address>
        <city>Aichi</city>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital; Hematology</name>
      <address>
        <city>Chiba</city>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital; Hematology, Oncology &amp; Cardiovascular medicine</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital; Hematology and Oncology</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu University Hospital; First Department of Internal Medicine</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital; Hematology</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital; Hematology</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital;Hematology and Oncology</name>
      <address>
        <city>Iwate</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital; Hematology, Rheumatology, Infectious Disease</name>
      <address>
        <city>Kanagawa</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital; Department of Hematology/Oncology</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital; Internal Medicine</name>
      <address>
        <city>Niigata</city>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital; Hematology</name>
      <address>
        <city>Okayama</city>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital; Hematology</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital; Hematology and Oncology</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital; Hematology and Rheumatology</name>
      <address>
        <city>Osaka</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital;Hematology</name>
      <address>
        <city>Shimane</city>
        <zip>693-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital; Hematology</name>
      <address>
        <city>Tochigi</city>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital; Hematology</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toranomon Hospital; Hematology</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital; Hematology</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR; Hematology Oncology</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeollanam-do</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital; Medical Oncology</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary'S Hospital, the Catholic University School of Medicine; Internal Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Estatal De Cancerologia De Chihuahua; Servicio De Hematologia Banco De Sangre</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose E. Gonzalez; Haematology</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oaxaca Site Management Organization</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios Clinicos de Queretaro, SC</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hemato Oncologico Panama</name>
      <address>
        <city>Panama</city>
        <zip>0832</zip>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto;Oncologico Miraflores</name>
      <address>
        <city>Lima</city>
        <zip>18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas</name>
      <address>
        <city>Lima</city>
        <zip>34</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Especialidades Medicas</name>
      <address>
        <city>Lima</city>
        <zip>Lima 41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny</name>
      <address>
        <city>Brzozów</city>
        <zip>36-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz; Hematology</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katedra i Klinika Hematoonkologii i Transplantacji Szpiku; Uniwersytetu Medycznego w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Uni of Wroclaw; Hematology</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary of Ministry of Health of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blokhin Cancer Research Center; Clinical Oncology</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital N.A. Semashko; Hematology</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penza Regional Oncology Dispensary</name>
      <address>
        <city>Penza</city>
        <zip>440071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital n.a. Baranov; Haematology</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Inst. of Hematology &amp; Blood Transfusion ; Hematology</name>
      <address>
        <city>St Petersburg</city>
        <zip>191024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Vojvodine; Clinic for Hematology</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Oncology Inst. ; Dept. of Haematology</name>
      <address>
        <city>Bratislava</city>
        <zip>833 10</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Constantiaberg Medical Clinic; Dept. of Haematology &amp; Bone Marrow Translant</name>
      <address>
        <city>Cape Town</city>
        <zip>7800</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Potter Oncology Centre</name>
      <address>
        <city>Groenkloof</city>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Centre of Rosebank; Oncology</name>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Donald Gordon Clinical Trial Centre; Medical Oncology</name>
      <address>
        <city>Parktown, Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drs Thomson, Brittain an Partners Inc</name>
      <address>
        <city>Pretoria</city>
        <zip>0044</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra, Servicio de Hematología</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus; Servicio de Oncologia</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial; Servicio de Hematología y Oncología</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal; Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra; Servicio de Oncologia</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena; Servicio de Oncologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau; Zentrum Für Onkologie, Hämatologie &amp; Transfusionsmedizin</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni; Oncologia</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden;Onkologie und Hämatologie</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans General Hospital; Division of Oncology</name>
      <address>
        <city>Taipei</city>
        <zip>00112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Universtiy Hospital; Division of Hematology</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital; Division of Hematology, Department of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Inst.</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajavithi Hospital; Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramathibodi Hospital; Division of Hematology, Department of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital; Division of Hematology, Department of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital, Khon Kaen Uni ; Dept of Medicine</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary; Haematology - Ward 16</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital; Department of Haematology</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital; Haematology</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The HOPE Clinical Trials Unit</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital; Dept. Of Haematology</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>India</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>August 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2017</results_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eleven participants withdrew from the study after randomization but prior to receiving study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rituximab+Chemotherapy</title>
          <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
        </group>
        <group group_id="P2">
          <title>Obinutuzumab+Chemotherapy</title>
          <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="712"/>
                <participants group_id="P2" count="706"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="712"/>
                <participants group_id="P2" count="706"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Continued in the study</title>
              <participants_list>
                <participants group_id="P1" count="446"/>
                <participants group_id="P2" count="455"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent-to-treat (ITT) population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Rituximab+Chemotherapy</title>
          <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
        </group>
        <group group_id="B2">
          <title>Obinutuzumab+Chemotherapy</title>
          <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="712"/>
            <count group_id="B2" value="706"/>
            <count group_id="B3" value="1418"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.1" spread="13.6"/>
                    <measurement group_id="B2" value="59.4" spread="13.3"/>
                    <measurement group_id="B3" value="59.2" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="329"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="666"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="383"/>
                    <measurement group_id="B2" value="369"/>
                    <measurement group_id="B3" value="752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS), Investigator-Assessed</title>
        <description>Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).</description>
        <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS), Investigator-Assessed</title>
          <description>Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3868</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by International Prognostic Index (IPI) score (low/low−intermediate (excluding participants having an IPI score 0 without bulky disease).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed</title>
        <description>Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).</description>
        <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed</title>
          <description>Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                    <measurement group_id="O2" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2736</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified by International Prognostic Index (IPI) score (low/low−intermediate (excluding participants having an IPI score 0 without bulky disease).</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.</description>
        <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR), Investigator-Assessed</title>
        <description>Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.</description>
        <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR), Investigator-Assessed</title>
          <description>Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without PET (n= 712, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.3"/>
                    <measurement group_id="O2" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With PET (n=665, 669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9"/>
                    <measurement group_id="O2" value="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR), IRC-Assessed</title>
        <description>Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.</description>
        <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR), IRC-Assessed</title>
          <description>Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without PET (n= 712, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2"/>
                    <measurement group_id="O2" value="82.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With PET (n=665, 669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1"/>
                    <measurement group_id="O2" value="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response (CR) at the End of Treatment, Investigator-Assessed</title>
        <description>Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.</description>
        <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR) at the End of Treatment, Investigator-Assessed</title>
          <description>Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without PET (n= 712, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With PET (n=665, 669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5"/>
                    <measurement group_id="O2" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Response (CR) at the End of Treatment, IRC-Assessed</title>
        <description>Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.</description>
        <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (CR) at the End of Treatment, IRC-Assessed</title>
          <description>Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Without PET (n= 712, 706)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With PET (n=665, 669)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-Free Survival (EFS), Investigator-Assessed</title>
        <description>Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non–protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.</description>
        <time_frame>Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-Free Survival (EFS), Investigator-Assessed</title>
          <description>Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non–protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-Free Survival (DFS), Investigator-Assessed</title>
        <description>Disease-free survival was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/relapse or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Reported is the percentage of participants with event.</description>
        <time_frame>Baseline up to death or disease progression, whichever occurred first, to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants, of which evaluable participants were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-Free Survival (DFS), Investigator-Assessed</title>
          <description>Disease-free survival was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/relapse or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 centimeter (cm) or &gt;/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. Reported is the percentage of participants with event.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants, of which evaluable participants were included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="397"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR), Investigator-Assessed</title>
        <description>DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: &gt;/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression &gt;/= 50%. Progression/relapse: at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 cm or &gt;/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%.</description>
        <time_frame>Baseline up to death or disease progression, whichever occurs first, to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants, of which evaluable participants were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR), Investigator-Assessed</title>
          <description>DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: &gt;/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression &gt;/= 50%. Progression/relapse: at least 50% increase in nodal lesions or &gt;/=50% increase in any node &gt; 1 cm or &gt;/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion &gt; 1.5 cm or &gt;/= 50% increase in any previously involved node with a diameter &lt;/= 1 cm such that it is now &gt;1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants, of which evaluable participants were included in this analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="659"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0">There were not enough events to calculate the confidence intervals.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="48.1">There were not enough events to calculate the median and the upper limit of the confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Next Anti-Lymphoma Treatment (TTNALT)</title>
        <description>Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause.</description>
        <time_frame>Baseline up to start of next anti-lymphoma treatment or death due to any cause, whichever occurred first, to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Next Anti-Lymphoma Treatment (TTNALT)</title>
          <description>Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median and 95% confidence interval were not calculable, due to low number of observations.</measurement>
                    <measurement group_id="O2" value="NA">Median and 95% confidence interval were not calculable, due to low number of observations.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
        <time_frame>Baseline up to data cut-off (up to approximately 4 years and 9 months)</time_frame>
        <population>The safety analysis population included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.</description>
          <population>The safety analysis population included all participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="703"/>
                <count group_id="O2" value="704"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9"/>
                    <measurement group_id="O2" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab</title>
        <description>The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants.</description>
        <time_frame>Pre-dose (Hour 0) on Cycle (C) 1 Day (D) 1, C4D1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)</time_frame>
        <population>The safety analysis population included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab</title>
          <description>The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants.</description>
          <population>The safety analysis population included all participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening (n=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1 (n=29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1 (n=89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Completion / Early Discontinuation (n=67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Month 6 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Month 12 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Month 18 (n=27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Month 24 (n=25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Month 30 (n=19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-Up Completion/ Early Discontinuation (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score</title>
        <description>The FACT-Lym subscale was developed to assess health-related quality of life in patients with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement.</description>
        <time_frame>Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 4 years and 9 months, (cycle length = 21 days)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score</title>
          <description>The FACT-Lym subscale was developed to assess health-related quality of life in patients with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=607, 641)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.36" spread="10.15"/>
                    <measurement group_id="O2" value="45.12" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score Change, Cycle 3 Day 1 (n=553, 565)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" spread="8.69"/>
                    <measurement group_id="O2" value="3.74" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score Change, Study Compl./Discont. (n=526, 529)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="10.26"/>
                    <measurement group_id="O2" value="4.43" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score Change, Follow-Up Month 12 (n=370, 412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="10.13"/>
                    <measurement group_id="O2" value="6.21" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score Change, Follow-Up Month 24 (n=232, 248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79" spread="10.26"/>
                    <measurement group_id="O2" value="5.95" spread="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score Change, Follow-Up Month 30 (n=0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants were evaluable.</measurement>
                    <measurement group_id="O2" value="25.00">There was only one reported value; therefore, no standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score Change, Follow-Up Month 36 (n=94, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.13" spread="10.18"/>
                    <measurement group_id="O2" value="6.88" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score Change, Follow-Up Month 48 (n=6, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="4.67"/>
                    <measurement group_id="O2" value="4.00" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score Change, Follow-Up Term./Compl. (n=50, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="12.57"/>
                    <measurement group_id="O2" value="3.60" spread="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores</title>
        <description>The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants.</description>
        <time_frame>Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 4 years and 9 months, (cycle length = 21 days)</time_frame>
        <population>The intent-to-treat (ITT) population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
          <group group_id="O2">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores</title>
          <description>The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants.</description>
          <population>The intent-to-treat (ITT) population included all randomized participants.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="706"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=610, 643)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.78" spread="24.47"/>
                    <measurement group_id="O2" value="58.51" spread="25.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Cycle 1 Day 1 (n=0, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">NA = NE = Not estimable based on 0 participants evaluated</measurement>
                    <measurement group_id="O2" value="NA">NA = NE = Not estimable based on 0 participants evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Cycle 3 Day 1 (n=555, 567)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" spread="24.08"/>
                    <measurement group_id="O2" value="7.52" spread="25.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Study Completion (n=526, 532)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.97" spread="26.14"/>
                    <measurement group_id="O2" value="10.29" spread="30.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Follow-Up Month 12 (n=370, 414)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.73" spread="26.32"/>
                    <measurement group_id="O2" value="13.89" spread="30.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Follow-Up Month 24 (n=234, 247)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.84" spread="26.30"/>
                    <measurement group_id="O2" value="14.74" spread="29.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Follow-Up Month 30 (n=0, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">NA = NE = Not estimable based on 0 participants evaluated</measurement>
                    <measurement group_id="O2" value="58.33">NA = NE = Not estimable based on 1 participant evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Follow-Up Month 36 (n=94, 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.36" spread="31.40"/>
                    <measurement group_id="O2" value="14.31" spread="31.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Follow-Up Month 48 (n=7, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.76" spread="39.04"/>
                    <measurement group_id="O2" value="14.17" spread="33.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change Baseline, Follow-Up Completion (n=50, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="33.25"/>
                    <measurement group_id="O2" value="-0.69" spread="24.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)</title>
        <description>Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab.</description>
        <time_frame>C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)</time_frame>
        <population>40 Japanese participants in the Obinutuzumab+Chemotherapy arm</population>
        <group_list>
          <group group_id="O1">
            <title>Obinutuzumab+Chemotherapy</title>
            <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)</title>
          <description>Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab.</description>
          <population>40 Japanese participants in the Obinutuzumab+Chemotherapy arm</population>
          <units>micrograms per milliliter (μg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1, Day 8 pre-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 15 pre-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1 pre-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="431" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 1 pre-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352" spread="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6, Day 1 pre-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378" spread="45.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8, Day 1 pre-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="478" spread="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 1 post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="435" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 1 20-28 hours after end of infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" spread="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 1 66-80 hours after end of infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219" spread="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 8 post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="578" spread="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1, Day 15 post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="718" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2, Day 1 post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="938" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4, Day 1 post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6, Day 1 post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="813" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8, Day 1 post-infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="881" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 9 months</time_frame>
      <desc>The safety analysis population included all participants who received at least one dose of study drug (i.e., obinutuzumab, rituximab, or CHOP).</desc>
      <group_list>
        <group group_id="E1">
          <title>Rituximab+Chemotherapy</title>
          <description>Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
        </group>
        <group group_id="E2">
          <title>Obinutuzumab+Chemotherapy</title>
          <description>Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="300" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Splenic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Ventricular flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Infective glossitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Neutropenic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Tuberculosis of central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>HIV antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Marginal zone lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Tumour perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Iiird nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Stroke in evolution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Vocal cord paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Cystitis glandularis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Venous occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA, version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="604" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="642" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="304" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="704"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="703"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="704"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

